• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial
Aadi Bioscience Closes $23 Million in Series A Funding
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Read More
Dave Lennon, PhD
Read More
Stephen Rodin, JD
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Read More
Richard Maroun, JD

Comments

Comments are closed.

  • Next Post
  • Previous Post